Evidence map›Paper›PMID 31075981›Full record

ArticleInternational journal of molecular sciences2019

Hyperbilirubinemia in Gunn Rats is Associated with Decreased Inflammatory Response in LPS-Mediated Systemic Inflammation.

Petra Valaskova, Ales Dvorak, Martin Lenicek, Katerina Zizalova, Nikolina Kutinova-Canova, Jaroslav Zelenka, Monika Cahova, Libor Vitek, Lucie Muchova

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Petra ValaskovaInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. petra.valaskova@lf1.cuni.cz.
Ales DvorakInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. aleshdvorak@gmail.com.ORCID 0000-0002-1285-6928
Martin LenicekInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. mleni@centrum.cz.
Katerina ZizalovaInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. katka.ziza@seznam.cz.
Nikolina Kutinova-CanovaInstitute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic. Nikolina.Canova@lf1.cuni.cz.
Jaroslav ZelenkaDepartment of Biochemistry and Microbiology, University of Chemistry and Technology, 16628 Prague, Czech Republic. jar.zelenka@gmail.com.ORCID 0000-0001-8145-8037
Monika CahovaDepartment of Experimental Diabetology, Institute of Clinical and Experimental Medicine, 14021 Prague, Czech Republic. moca@ikem.cz.
Libor VitekInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. vitek@cesnet.cz.ORCID 0000-0002-5318-0151
Lucie MuchovaInstitute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 12108, Czech Republic. lucie.muchova@lf1.cuni.cz.ORCID 0000-0003-2082-1060
Charles University · CZInstitute of Clinical and Experimental Medicine · CZUniversity of Chemistry and Technology, Prague · CZ

Funding

Ministerstvo Zdravotnictví Ceské Republiky RVO-VFN64165/2018Univerzita Karlova v Praze GAUK No. 168216 and SVV 260370/2018
6 · The paper itself

Abstract

Decreased inflammatory status has been reported in subjects with mild unconjugated hyperbilirubinemia. However, mechanisms of the anti-inflammatory actions of bilirubin (BR) are not fully understood. The aim of this study is to assess the role of BR in systemic inflammation using hyperbilirubinemic Gunn rats as well as their normobilirubinemic littermates and further in primary hepatocytes. The rats were treated with lipopolysaccharide (LPS, 6 mg/kg intraperitoneally) for 12 h, their blood and liver were collected for analyses of inflammatory and hepatic injury markers. Primary hepatocytes were treated with BR and TNF-α. LPS-treated Gunn rats had a significantly decreased inflammatory response, as evidenced by the anti-inflammatory profile of white blood cell subsets, and lower hepatic and systemic expressions of IL-6, TNF-α, IL-1β, and IL-10. Hepatic mRNA expression of LPS-binding protein was upregulated in Gunn rats before and after LPS treatment. In addition, liver injury markers were lower in Gunn rats as compared to in LPS-treated controls. The exposure of primary hepatocytes to TNF-α with BR led to a milder decrease in phosphorylation of the NF-κB p65 subunit compared to in cells without BR. In conclusion, hyperbilirubinemia in Gunn rats is associated with an attenuated systemic inflammatory response and decreased liver damage upon exposure to LPS.

Indexed as

AnimalsApoptosisBilirubinBiomarkersCells, CulturedCytokinesCytoprotectionFemaleHepatocytesHyperbilirubinemiaInflammationLeukocytesLipopolysaccharidesLiverNF-kappa BPhosphorylationBilirubinBiomarkersCytokinesLipopolysaccharidesNF-kappa BRNA, MessengerbilirubinGunn ratshyperbilirubinemiainflammationLPSNF-κB

Identifiers

PMID31075981
PMCPMC6539717
OpenAlexW2944754180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.